Nippon Steel persists with its $15B acquisition of U.S. Steel, highlighting its commitment to American growth, despite Biden's preference for U.S. ownership, promising no layoffs and engaging with unions to secure support amidst political scrutiny.
The Alliance for Automotive Innovation urges the Biden administration to oppose Cleveland-Cliffs' potential acquisition of US Steel due to concerns of anti-competitive pricing for vehicles and the monopolistic control of domestic steel production.
Lee Enterprises adopts a poison pill strategy in response to Quint Digital's accumulation of over 12.4% of its stock, citing potential competition with its subsidiary BLOX Digital in the North American media tech market.
Doma (NYSE:DOMA) to be acquired by Title Resources Group in all-cash transaction at $6.29 per share, with Doma's divisions to operate as TRG subsidiaries, leading to a 43.0% premium over closing share price and a 34% surge in after-hours trading.
Take-Two Interactive Software (NASDAQ:TTWO) will acquire The Gearbox Entertainment Company for $460M in newly issued shares, based on the average closing price over the last five days, expected to be finalized in Q1 of Fiscal Year 2025, excluding non-core assets.
Xos (NASDAQ:XOS) has finalized its acquisition of ElectraMeccanica Vehicles (NASDAQ:SOLO), boosting its balance sheet by approximately $48 million and providing growth capital, following the terms announced on January 11 in an all-stock transaction.
Vimeo's (NASDAQ: VMEO) 28% stock drop coincides with speculation of potential acquisition by Bending Spoons SpA amid its market cap of $912 million and a significant decline since its spin-off from IAC/Interactive Corp.
Blackstone explores £1.5 billion sale of The Office Group, aiming for gains amid WeWork's collapse, eyeing deal by Q1 2025 amidst rising demand for flexible office space.
Cartica Acquisition Corp plans to extend its initial business combination deadline, with the Sponsor committing to contribute $40,000 monthly until January 7, 2025, contingent on shareholder approval, impacting per-share amounts and potential redemptions.
The FDA grants full approval for AbbVie's Elahere, a drug for treating ovarian cancer, following its initial accelerated approval in November 2022, based on data from the MIRASOL Phase 3 study, after AbbVie's acquisition of ImmunoGen for approximately $10 billion.
